Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dexamethasone 4mg Clear all
Completed Phase 2 Interventional Results available

Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma

NCT01159574
View directory record Official record
Conditions
Multiple Myeloma
Interventions
dexamethasone, clarithromycin, Pomalidomide
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Sep 24, 2026, 4:06 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma

NCT01979276
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Romidepsin, pomalidomide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 24, 2026, 4:06 PM EDT
Terminated Phase 4 Interventional Results available

Continuous Nerve Block Block vs Combination of Single Block Plus Intravenous Lidocaine for Postoperative Pain.

NCT04208516
View directory record Official record
Conditions
Postoperative Pain
Interventions
Continuous Erector Spinae Plane Nerve Block, Continuous Quadratus Lumborum Nerve Block, Single Erector Spinae Plane Nerve Block, Single Quadratus Lumborum Nerve Block, Lidocaine IV, Ropivacaine 0.5% Injectable Solution, Dexamethasone, Dexmedetomidine, Lidocaine
Procedure · Drug
Lead sponsor
Jeremy Kearns
Other
Eligibility
18 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 24, 2026, 4:06 PM EDT
Enrolling by invitation Phase 4 Interventional

Post-operative Methylprednisolone Taper Course for Orthopedic Surgery

NCT03661645
View directory record Official record
Conditions
Orthopedic Surgeries
Interventions
10 mg IV dexamethasone & 6 day oral methylprednisolone taper, 10 mg IV dexamethasone
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 24, 2026, 4:06 PM EDT
Recruiting Early Phase 1 Interventional

Does Nerve Block + Oral Dexamethasone Reduce Recurrence of Headache Within 72 Hrs?

NCT06016465
View directory record Official record
Conditions
Migraine
Interventions
Dexamethasone Oral, Placebo
Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dexamethasone in Total Knee Arthroplasty

NCT05018091
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Dexamethasone 4mg, Dexamethasone 8 Mg/mL Injectable Suspension, Dexamethasone 16mg
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
10
States / cities
Redwood City, California • San Francisco, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 24, 2026, 4:06 PM EDT
Terminated Phase 1 Interventional

Platelet Rich Plasma vs. Corticosteroid Injection in the Treatment of Partial Rotator Cuff Tears

NCT01688362
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
Platelet Rich Plasma (PRP), Corticosteroid
Biological · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 4 Interventional Results available

Dexamethasone for Migraine - Dose Comparison

NCT04112823
View directory record Official record
Conditions
Migraine
Interventions
Dexamethasone 4mg, Dexamethasone 16mg
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Preoperative Levator Ani Muscle Injection and Pudendal Nerve Block for Pain Control After Vaginal Reconstructive Surgery

NCT03040011
View directory record Official record
Conditions
Pelvic Organ Prolapse, Surgery, Postoperative Pain
Interventions
Dexamethasone, Bupivacaine, Bilateral Pudendal Nerve Block, Bilateral Levator Ani Muscle Injection, Saline
Drug · Procedure
Lead sponsor
Lauren Giugale, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2020 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain

NCT04123561
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
TLC599, DSP, Normal Saline
Drug · Other
Lead sponsor
Taiwan Liposome Company
Industry
Eligibility
40 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
41
States / cities
Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 24, 2026, 4:06 PM EDT
Terminated Phase 2 Interventional

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

NCT02188368
View directory record Official record
Conditions
Multiple Myeloma
Interventions
POM, Steroids, PLD, CFZ, BTZ, CLA, CY
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
12
States / cities
Encinitas, California • Fountain Valley, California • Palm Springs, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Sep 24, 2026, 4:06 PM EDT
Terminated Phase 3 Interventional Results available

Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders

NCT02266433
View directory record Official record
Conditions
DeQuervains Tenosynovitis, Lateral Epicondylitis, Tennis Elbow, Trigger Finger, Tenosynovitis, Inflammatory Disease
Interventions
Ketorolac, Dexamethasone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2020 · Synced Sep 24, 2026, 4:06 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas

NCT05768919
View directory record Official record
Conditions
Glioblastoma
Interventions
Treatment Period 1, Treatment Period 2, Treatment Period 3, Treatment Period 4a
Drug
Lead sponsor
SignPath Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Intravenous Dexamethasone on Supraclavicular Brachial Plexus Block for Shoulder Arthroscopy

NCT02688530
View directory record Official record
Conditions
Shoulder Arthroscopy, Pain
Interventions
IV Saline, IV Dexamethasone 4mg, IV Dexamethasone 6mg, IV Dexamethasone 8mg
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Sep 24, 2026, 4:06 PM EDT
Terminated Phase 2 Interventional

Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

NCT03590652
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Ixazomib, Pomalidomide, Dexamethasone, Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 24, 2026, 4:06 PM EDT
Recruiting Phase 1Phase 2 Interventional

Selinexor and Backbone Treatments of Multiple Myeloma Patients

NCT02343042
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin, Mezigdomide
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
16
States / cities
Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 24, 2026, 4:06 PM EDT
Terminated Phase 2 Interventional Results available

Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer

NCT00479089
View directory record Official record
Conditions
Bladder Cancer
Interventions
Docetaxel, ZD1839, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2015 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 4 Interventional Results available

the Analgesic Duration of Dexmedetomidine Compared to Dexamethasone as Adjuncts to Single Shot Interscalene Block

NCT02653144
View directory record Official record
Conditions
Opioid Use, Unspecified
Interventions
Ropivacaine, Dexmedetomidine, Dexamethasone
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction

NCT02525718
View directory record Official record
Conditions
Breast Cancer
Interventions
Saline, 0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 24, 2026, 4:06 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics

NCT02297230
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation Therapy (RT), Capecitabine, Trastuzumab, Paclitaxel
Radiation · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced Sep 24, 2026, 4:06 PM EDT
Not yet recruiting Phase 4 Interventional

Dose Dependent Steroid Injections

NCT07494136
View directory record Official record
Conditions
Lumbar Radiculopathy, Sciatica, Back Pain With Radiation
Interventions
Triamcinolone 10 Mg/mL Injectable Suspension, Triamcinolone 40 Mg/mL Injectable Suspension, Triamcinolone 80 Mg/mL Injectable Suspension, Dexamethasone 2 MG, Dexamethasone 4mg, Dexamethasone 8 MG
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 24, 2026, 4:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

NCT02119468
View directory record Official record
Conditions
Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma
Interventions
ixazomib citrate, dexamethasone, pomalidomide
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
5
States / cities
Scottsdale, Arizona • Duarte, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 24, 2026, 4:06 PM EDT
Withdrawn Phase 3 Interventional

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

NCT00226668
View directory record Official record
Conditions
Brain Edema, Brain Tumor
Interventions
hCRF, placebo hCRF
Drug
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
24
States / cities
Phoenix, Arizona • La Jolla, California • Newport Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2008 · Synced Sep 24, 2026, 4:06 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Low Dose Dexamethasone for Distal Radius Fractures

NCT05274113
View directory record Official record
Conditions
Post Operative Pain, Distal Radius Fracture
Interventions
Dexamethasone 4mg, Ropivacaine
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 24, 2026, 4:06 PM EDT